CADRENAL THERAPEUTICS INC

Cadrenal insider selling reveals cautious confidence: CEO Pham Quang X’s rule‑based sales amid steep price drop, yet long‑term stake suggests potential upside for patient‑disease investors.

Cadrenal insider selling: Pham Quang X’s recent trades show a sustained, low‑price liquidation pattern under Rule 10b‑5‑1, hinting at portfolio rebalancing and potential impact on a weak‑market‑cap biotech stock.

Cadrenal insider sale: CEO Pham Quang X sells 1,165 shares at $5.69, reflecting liquidity needs amid a 62% year‑to‑date decline and potential future funding challenges.